Riskpilot← Back to searchSign inGet full accessUNI PHARMA HOLDING AS
ASActiveOrg 981962583Holandsfjord, 8178 HalsaManufacture of homogenised food preparations and dietetic food · NACE 1086Est. 20000 employees
Revenue 2025
NOK 0
EBITDA margin
—
-127% vs 2024
Equity ratio
31.2%
Financial strength
Net profit 2025
NOK -24K
-115% vs 2024
| Revenue | NOK 0 | — |
| EBITDA | NOK -36K | -127% |
| Net profit | NOK -24K | -115% |
| Total assets | NOK 659K | -7% |
| Equity | NOK 206K | -69% |
| Employees | 0 | — |
Legal name
UNI PHARMA HOLDING AS
Org number
981962583
Legal form
Aksjeselskap
NACE code
1086 · Manufacture of homogenised food preparations and dietetic food
Founded
27. mai 2000
Share capital
NOK 70 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Daglig leder alene.
Company purpose
Utvikling. Produksjon og salg av helostprodukter. Og det som naturlig hører hertil herunder investering i andre selskaper.
Address
Holandsfjord, 8178 Halsa
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 20 | 150 | 150 | 150 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −141 | 86 | 136 | 134 | −36 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −141 | 86 | 136 | 134 | −36 |
| Net financials | 0 | 2 | 5 | 26 | 12 |
| Profit before tax | −140 | 88 | 141 | 159 | −24 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −140 | 88 | 141 | 159 | −24 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 499 | 592 | 546 | 710 | 659 |
| Equity | 285 | 373 | 515 | 674 | 206 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 213 | 219 | 32 | 36 | 453 |
| Total debt | 213 | 219 | 32 | 36 | 453 |
EBITDA margin
-3591100.0%
This company
15.8%
Market median
-22728581% vs market
20212025
Equity ratio
31.2%
This company
38.2%
Market median
+18% vs market
20212025
Return on equity
-11.5%
This company
18.4%
Market median
-163% vs market
20212025
Net profit margin
-2358200.0%
This company
8.1%
Market median
-29113680% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
2.20×
This company
0.62×
Market median
-255% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
VP Deputy Member | Deputy Member | 2011 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Chairman | 2011 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 30% | 30% | 2022 | |
| Individual | 25% | 25% | 2022 | |
| Individual | 4.5% | 4.5% | 2022 | |
| Individual | 4.5% | 4.5% | 2022 | |
| Individual | 4.5% | 4.5% | 2022 | |
| Individual | 4.5% | 4.5% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of UNI PHARMA HOLDING AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Vigdis Petra Hagen Wold | Deputy Member | 0 companies |
| Alf Egil Hagen | Deputy Chairman | 0 companies |